DOI:
10.1055/s-00000045
Der Nuklearmediziner
Issue 02 ·
Volume 36 ·
June 2013
DOI: 10.1055/s-003-25187
Aktuell referiert
71
71
72
73
74
75
76
77
78
Lymphome: Diagnostik und Therapie
79
Dietlein, M.;
Kuhnert, G.;
Kahraman, D.;
Engert, A.;
Borchmann, P.;
Fuchs, M.;
Baues, C.;
Eich, H.;
Drzezga, A.;
Kobe, C.:
Early Interim PET/CT in Hodgkin Lymphoma of Adults – From Risk Stratification to Therapy Stratification
86
Kobe, C.;
Kuhnert, G.;
Kahraman, D.;
Holstein, A.;
Hungenbach, S.;
Engert, A.;
Borchmann, P.;
Fuchs, M.;
Eich, H.;
Kriz, J.;
Baues, C.;
Drzezga, A.;
Dietlein, M.:
Can We Use PET/CT for the Decision for or against Radiotherapy after First Line Chemotherapy
92
107
Pezzutto, A.;
Scholz, C. W.:
Radioimmunotherapy of Malignant Lymphomas with 90Yttrium-Ibritumomab Tiuxetan: Overview of Current Use
CME Fortbildung
96
Kurch, L.;
Sabri, O.;
Kluge, R.:
The Role of FDG-PET/CT in Paediatric and Adolescent Lymphoma Patients with Special Consideration of Hodgkin‘s Lymphoma
Kasuistik aus der täglichen Praxis
113
Fendler, W. P.;
Coppenrath, E.;
Pfluger, T.:
PET/MRI in Pediatric Oncology: A 12-Year Old Boy Presents with Knee Pain
Recht und Wirtschaft
115
120
